亘利生物科技（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting 2023-09-06 20:00
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors 2023-08-07 23:14
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting 2023-06-04 02:15
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) 2023-05-15 19:00
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress 2023-05-12 05:28
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting 2023-04-26 22:15
Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference 2023-02-28 21:00
Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 2023-02-27 21:00
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma 2023-02-13 20:30
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma 2023-02-03 20:30
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate 2022-12-11 07:15
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences 2022-11-23 21:00
Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award 2022-11-16 21:00
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition 2022-11-03 21:10
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 2022-10-31 21:00
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences 2022-10-24 21:00
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia 2022-10-17 20:05
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-09-14 20:30
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences 2022-08-29 21:00
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022 2022-08-02 21:00
1 2 3 4